Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program
06. Februar 2025 08:30 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response...
Rakovina Therapeutics Announces Listing on Frankfurt Stock Exchange
30. Januar 2025 12:16 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel...
Rakovina Therapeutics to Participate in BioInnovate UBC Annual Conference
29. Januar 2025 08:30 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company advancing innovative cancer therapies through artificial...
Rakovina Therapeutics Comments on $500 Billion AI Infrastructure Investment and Its Implications for Healthcare Innovation
22. Januar 2025 07:30 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company at the forefront of AI-driven drug discovery, yesterday commented...
Rakovina Therapeutics Announces Key Milestone in Cancer Drug Innovation in Collaboration with Variational AI
13. Januar 2025 08:30 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel...
Rakovina Therapeutics Announces Receipt of AI-Derived Drug Candidates and Advancement to Preclinical Validation
06. Januar 2025 08:30 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company focused on the development of new cancer therapies based on novel...
Rakovina Therapeutics to Connect with Industry Leaders During 43rd Annual J.P. Morgan Healthcare Conference Week
03. Januar 2025 16:30 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics, Inc. (TSX: RKV), a biopharmaceutical company focused on the development of new cancer therapies based on novel...
Rakovina Therapeutics: Reflecting on 2024 Success and Building Momentum for a Transformative 2025
19. Dezember 2024 07:55 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) a biopharmaceutical company focused on the development of new...
Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations
17. Dezember 2024 21:55 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) announces that in accordance with the terms of an indenture...
Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement
13. Dezember 2024 18:50 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”, “Rakovina”, or “Rakovina Therapeutics”) a biopharmaceutical company committed to...